A recent study highlights the potential of polygenic Alzheimer's risk scores to predict the accumulation of brain amyloid-beta and determine the age of disease onset. Amyloid-beta accumulation is a primary hallmark of Alzheimer's disease that typically begins several decades before any clinical symptoms manifest. Additionally, the research utilized data from 2,175 participants in the Alzheimer's Dementia Onset and Progression in International Cohorts (ADOPIC) study.

Researchers discovered that higher genetic risk scores significantly increased the odds of amyloid accumulation. Specifically, individuals with elevated risk profiles showed an odds ratio of 1.16 for becoming accumulators. Moreover, these scores predicted a younger age at which amyloid levels crossed the critical 20 centiloid threshold. Furthermore, the findings indicate that these risk markers function independently of the patient's APOE ε4 status.

Clinical Implications of Polygenic Alzheimer's Risk Scores

Interestingly, the study also developed scores for genetic resilience. Higher resilience scores predicted a significantly later age of onset for amyloid buildup. However, resilience did not directly influence whether an individual would start accumulating amyloid initially. This distinction suggests that different genetic factors govern the start of pathology versus the speed of its progression.

Clinicians may soon use these genetic tools to identify patients who are likely to develop pathology early. This identification creates a vital window for implementing disease-modifying treatments or lifestyle changes. Consequently, early prediction could potentially delay or even prevent the symptomatic onset of Alzheimer's disease. This approach represents a shift toward personalized preventive neurology.

How do polygenic Alzheimer's risk scores differ from standard APOE testing?

While APOE ε4 is the strongest individual genetic risk factor, polygenic scores combine thousands of smaller genetic variations. This comprehensive approach provides a more nuanced risk profile and can predict the timing of amyloid accumulation even in patients without the APOE ε4 allele.

What is the clinical value of predicting the age of amyloid onset?

Predicting the age of onset allows healthcare providers to identify a specific window for intervention. This timing is crucial for administering disease-modifying treatments or suggesting lifestyle changes before irreversible cognitive decline occurs.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of a qualified healthcare provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

O'Brien EK et al. Predicting accumulation and age at onset of amyloid-β from genetic risk and resilience for Alzheimer's disease. EBioMedicine. 2026 Jun 12. doi: undefined. PMID: 42284682.

Vandenberghe R, et al. Association of Alzheimer's disease polygenic risk scores with amyloid accumulation in cognitively intact older adults. Alzheimers Res Ther. 2022 Sep 23;14(1):137.

Son HJ, et al. Association of Resilience-Related Life Experiences on Variability on Age of Onset in Dominantly Inherited Alzheimer Disease. Neurology. 2024 Dec 17;103(12):e209766.